RSS-Feed abonnieren
Bitte kopieren Sie die angezeigte URL und fügen sie dann in Ihren RSS-Reader ein.
https://www.thieme-connect.de/rss/thieme/de/10.1055-s-00000049.xml
PDF herunterladen
Clin Colon Rectal Surg 2023; 36(06): 415-422
DOI: 10.1055/s-0043-1767705
DOI: 10.1055/s-0043-1767705
Review Article
Impact of Molecular Status on Cytoreductive Surgery for Peritoneal Metastases from Colorectal Cancer
Autor*innen
Funding This study is supported by National Key Clinical Discipline, the Guangzhou Science and Technology Bureau, Guangzhou, China (2023A04J2245), and the Sixth Affiliated Hospital, Sun Yat-Sen University Clinical Research –‘1010’Program:1010CG(2022)-08.
Abstract
Colorectal cancer peritoneal metastases (CRC-PM) are present in 5 to 15% of instances of CRC, and the overall survival (OS) of patients with CRC-PM is much lower than that of patients with other isolated metastatic locations. In recent years, the introduction of cytoreductive surgery (CRS) in conjunction with hyperthermic intraperitoneal chemotherapy has resulted in a significant improvement in CRC-PM patients' OS. Despite this, a significant proportion of CRS patients continue to suffer complications of grades III to V or even die during the perioperative period. Early diagnosis, optimization of patient selection criteria, and refining of individualized combination therapy are necessary for these patients. In this review, we evaluate studies examining the relationship between molecular status and CRS in CRC-PM. Our objective is to gain a comprehensive understanding of how the altered molecular status of CRC-PM impacts CRS, which could increase the likelihood of tailored therapy in the future.
Keywords
molecular status - biomarkers - cytoreductive surgery - peritoneal metastasis - colorectal cancerPublikationsverlauf
Artikel online veröffentlicht:
16. April 2023
© 2023. Thieme. All rights reserved.
Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA
-
References
- 1 Sung H, Ferlay J, Siegel RL. et al. Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2021; 71 (03) 209-249
- 2 Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin 2018; 68 (06) 394-424
- 3 Arnold M, Sierra MS, Laversanne M, Soerjomataram I, Jemal A, Bray F. Global patterns and trends in colorectal cancer incidence and mortality. Gut 2017; 66 (04) 683-691
- 4 Bhat AA, Nisar S, Singh M. et al. Cytokine- and chemokine-induced inflammatory colorectal tumor microenvironment: emerging avenue for targeted therapy. Cancer Commun (Lond) 2022; 42 (08) 689-715
- 5 Koppe MJ, Boerman OC, Oyen WJG, Bleichrodt RP. Peritoneal carcinomatosis of colorectal origin: incidence and current treatment strategies. Ann Surg 2006; 243 (02) 212-222
- 6 Kim CH. Molecular analyses in peritoneal metastasis from colorectal cancer: a review-an English version. J Anus Rectum Colon 2022; 6 (04) 197-202
- 7 Lemmens VE, Klaver YL, Verwaal VJ, Rutten HJ, Coebergh JW, de Hingh IH. Predictors and survival of synchronous peritoneal carcinomatosis of colorectal origin: a population-based study. Int J Cancer 2011; 128 (11) 2717-2725
- 8 Jayne DG, Fook S, Loi C, Seow-Choen F. Peritoneal carcinomatosis from colorectal cancer. Br J Surg 2002; 89 (12) 1545-1550
- 9 Franko J, Shi Q, Meyers JP. et al; Analysis and Research in Cancers of the Digestive System (ARCAD) Group. Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database. Lancet Oncol 2016; 17 (12) 1709-1719
- 10 Franko J, Shi Q, Goldman CD. et al. Treatment of colorectal peritoneal carcinomatosis with systemic chemotherapy: a pooled analysis of north central cancer treatment group phase III trials N9741 and N9841. J Clin Oncol 2012; 30 (03) 263-267
- 11 Verwaal VJ, Bruin S, Boot H, van Slooten G, van Tinteren H. 8-year follow-up of randomized trial: cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy in patients with peritoneal carcinomatosis of colorectal cancer. Ann Surg Oncol 2008; 15 (09) 2426-2432
- 12 Verwaal VJ, van Ruth S, de Bree E. et al. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol 2003; 21 (20) 3737-3743
- 13 Glehen O, Mithieux F, Osinsky D. et al. Surgery combined with peritonectomy procedures and intraperitoneal chemohyperthermia in abdominal cancers with peritoneal carcinomatosis: a phase II study. J Clin Oncol 2003; 21 (05) 799-806
- 14 März L, Piso P. Treatment of peritoneal metastases from colorectal cancer. Gastroenterol Rep (Oxf) 2015; 3 (04) 298-302
- 15 Goéré D, Malka D, Tzanis D. et al. Is there a possibility of a cure in patients with colorectal peritoneal carcinomatosis amenable to complete cytoreductive surgery and intraperitoneal chemotherapy?. Ann Surg 2013; 257 (06) 1065-1071
- 16 Kuijpers AMJ, Mirck B, Aalbers AG. et al. Cytoreduction and HIPEC in the Netherlands: nationwide long-term outcome following the Dutch protocol. Ann Surg Oncol 2013; 20 (13) 4224-4230
- 17 Glehen O, Gilly FN, Boutitie F. et al; French Surgical Association. Toward curative treatment of peritoneal carcinomatosis from nonovarian origin by cytoreductive surgery combined with perioperative intraperitoneal chemotherapy: a multi-institutional study of 1,290 patients. Cancer 2010; 116 (24) 5608-5618
- 18 Sluiter N, de Cuba E, Kwakman R, Kazemier G, Meijer G, Te Velde EA. Adhesion molecules in peritoneal dissemination: function, prognostic relevance and therapeutic options. Clin Exp Metastasis 2016; 33 (05) 401-416
- 19 de Cuba EMV, Kwakman R, van Egmond M. et al. Understanding molecular mechanisms in peritoneal dissemination of colorectal cancer: future possibilities for personalised treatment by use of biomarkers. Virchows Arch 2012; 461 (03) 231-243
- 20 Hulshof EC, Lim L, de Hingh IHJT, Gelderblom H, Guchelaar HJ, Deenen MJ. Genetic variants in DNA repair pathways as potential biomarkers in predicting treatment outcome of intraperitoneal chemotherapy in patients with colorectal peritoneal metastasis: a systematic review. Front Pharmacol 2020; 11: 577968
- 21 Vaghi C, Mauri G, Agostara AG. et al. The predictive role of ERBB2 point mutations in metastatic colorectal cancer: a systematic review. Cancer Treat Rev 2023; 112: 102488
- 22 Janssen JBE, Medema JP, Gootjes EC, Tauriello DVF, Verheul HMW. Mutant RAS and the tumor microenvironment as dual therapeutic targets for advanced colorectal cancer. Cancer Treat Rev 2022; 109: 102433
- 23 Datta J, Narayan RR, Goldman DA. et al. Distinct genomic profiles are associated with conversion to resection and survival in patients with initially unresectable colorectal liver metastases treated with systemic and hepatic artery chemotherapy. Ann Surg 2022; 276 (05) e474-e482
- 24 Chatila WK, Kim JK, Walch H. et al. Genomic and transcriptomic determinants of response to neoadjuvant therapy in rectal cancer. Nat Med 2022; 28 (08) 1646-1655
- 25 Li S, Balmain A, Counter CM. A model for RAS mutation patterns in cancers: finding the sweet spot. Nat Rev Cancer 2018; 18 (12) 767-777
- 26 Siesing C, Petersson A, Ulfarsdottir T. et al. Delineating the intra-patient heterogeneity of molecular alterations in treatment-naïve colorectal cancer with peritoneal carcinomatosis. Mod Pathol 2022; 35 (07) 979-988
- 27 Van Cutsem E, Cervantes A, Adam R. et al. ESMO consensus guidelines for the management of patients with metastatic colorectal cancer. Ann Oncol 2016; 27 (08) 1386-1422
- 28 Cox AD, Fesik SW, Kimmelman AC, Luo J, Der CJ. Drugging the undruggable RAS: mission possible?. Nat Rev Drug Discov 2014; 13 (11) 828-851
- 29 Allegra CJ, Rumble RB, Hamilton SR. et al. Extended RAS gene mutation testing in metastatic colorectal carcinoma to predict response to anti-epidermal growth factor receptor monoclonal antibody therapy: American Society of Clinical Oncology Provisional Clinical Opinion Update 2015. J Clin Oncol 2016; 34 (02) 179-185
- 30 Therkildsen C, Bergmann TK, Henrichsen-Schnack T, Ladelund S, Nilbert M. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: a systematic review and meta-analysis. Acta Oncol 2014; 53 (07) 852-864
- 31 Breuer E, Hebeisen M, Schneider MA. et al. Site of recurrence and survival after surgery for colorectal peritoneal metastasis. J Natl Cancer Inst 2021; 113 (08) 1027-1035
- 32 Morgan Z, Chow BE, Strong EA. et al. RAS mutation status confers prognostic relevance in patients treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal cancer. J Surg Res 2019; 240: 130-135
- 33 Schneider MA, Eden J, Pache B. et al. Mutations of RAS/RAF proto-oncogenes impair survival after cytoreductive surgery and HIPEC for peritoneal metastasis of colorectal origin. Ann Surg 2018; 268 (05) 845-853
- 34 Arjona-Sanchez A, Rodriguez-Ortiz L, Baratti D. et al. RAS mutation decreases overall survival after optimal cytoreductive surgery and hyperthermic intraperitoneal chemotherapy of colorectal peritoneal metastasis: a modification proposal of the peritoneal surface disease severity score. Ann Surg Oncol 2019; 26 (08) 2595-2604
- 35 Baratti D, Kusamura S, Niger M. et al. Prognostic impact of primary side and RAS/RAF mutations in a surgical series of colorectal cancer with peritoneal metastases. Ann Surg Oncol 2021; 28 (06) 3332-3342
- 36 Bhullar D, O'Dwyer S, Wilson M. et al. RAS mutation status should not be used to predict outcome from cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for colorectal peritoneal metastases. Ann Surg Oncol 2023; 30 (02) 792-801
- 37 Tonello M, Baratti D, Sammartino P. et al. Microsatellite and RAS/RAF mutational status as prognostic factors in colorectal peritoneal metastases treated with cytoreductive surgery and hyperthermic intraperitoneal chemotherapy (HIPEC). Ann Surg Oncol 2022; 29 (06) 3405-3417
- 38 Solomon D, Leigh N, Bekhor E. et al. The role of molecular biomarkers in outcomes and patient selection for cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for peritoneal metastases of colorectal origin. Surgeon 2021; 19 (06) e379-e385
- 39 Graf W, Cashin PH, Ghanipour L. et al. Prognostic impact of BRAF and KRAS mutation in patients with colorectal and appendiceal peritoneal metastases scheduled for CRS and HIPEC. Ann Surg Oncol 2020; 27 (01) 293-300
- 40 Diehl TM, Abbott DE. Molecular determinants and other factors to guide selection of patients for hepatic resection of metastatic colorectal cancer. Curr Treat Options Oncol 2021; 22 (09) 82
- 41 Sasaki Y, Hamaguchi T, Yamada Y. et al. Value of KRAS, BRAF, and PIK3CA mutations and survival benefit from systemic chemotherapy in colorectal peritoneal carcinomatosis. Asian Pac J Cancer Prev 2016; 17 (02) 539-543
- 42 Morkel M, Riemer P, Bläker H, Sers C. Similar but different: distinct roles for KRAS and BRAF oncogenes in colorectal cancer development and therapy resistance. Oncotarget 2015; 6 (25) 20785-20800
- 43 Ubink I, van Eden WJ, Snaebjornsson P. et al. Histopathological and molecular classification of colorectal cancer and corresponding peritoneal metastases. Br J Surg 2018; 105 (02) e204-e211
- 44 Richman SD, Seymour MT, Chambers P. et al. KRAS and BRAF mutations in advanced colorectal cancer are associated with poor prognosis but do not preclude benefit from oxaliplatin or irinotecan: results from the MRC FOCUS trial. J Clin Oncol 2009; 27 (35) 5931-5937
- 45 Péron J, Mercier F, Tuech JJ. et al; on behalf BIG-RENAPE working groups. The location of the primary colon cancer has no impact on outcomes in patients undergoing cytoreductive surgery for peritoneal metastasis. Surgery 2019; 165 (02) 476-484
- 46 Larsen SG, Goscinski MA, Dueland S. et al. Impact of KRAS, BRAF and microsatellite instability status after cytoreductive surgery and HIPEC in a national cohort of colorectal peritoneal metastasis patients. Br J Cancer 2022; 126 (05) 726-735
- 47 Flood MP, Jain A, Mitchell C. et al. The impact of molecular and mismatch repair status on the survival outcomes of surgically treated patients with colorectal peritoneal metastases. Eur J Surg Oncol 2022; 48 (10) 2218-2225
- 48 Kopetz S, Grothey A, Yaeger R. et al. Encorafenib, binimetinib, and cetuximab in BRAF V600E-mutated colorectal cancer. N Engl J Med 2019; 381 (17) 1632-1643
- 49 Hanahan D, Weinberg RA. Hallmarks of cancer: the next generation. Cell 2011; 144 (05) 646-674
- 50 Gupta GP, Massagué J. Cancer metastasis: building a framework. Cell 2006; 127 (04) 679-695
- 51 Nieves BJ, D'Amore PA, Bryan BA. The function of vascular endothelial growth factor. Biofactors 2009; 35 (04) 332-337
- 52 Shaheen RM, Tseng WW, Vellagas R. et al. Effects of an antibody to vascular endothelial growth factor receptor-2 on survival, tumor vascularity, and apoptosis in a murine model of colon carcinomatosis. Int J Oncol 2001; 18 (02) 221-226
- 53 Passot G, Bakrin N, Garnier L. et al. Intraperitoneal vascular endothelial growth factor burden in peritoneal surface malignancies treated with curative intent: the first step before intraperitoneal anti-vascular endothelial growth factor treatment?. Eur J Cancer 2014; 50 (04) 722-730
- 54 de Cuba EMV, de Hingh IH, Sluiter NR. et al. Angiogenesis-related markers and prognosis after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy for metastatic colorectal cancer. Ann Surg Oncol 2016; 23 (05) 1601-1608
- 55 Chia CS, Glehen O, Bakrin N. et al. Intraperitoneal vascular endothelial growth factor: a prognostic factor and the potential for intraperitoneal bevacizumab use in peritoneal surface malignancies. Ann Surg Oncol 2015; 22 (suppl 03): S880-S887
- 56 Logan-Collins JM, Lowy AM, Robinson-Smith TM. et al. VEGF expression predicts survival in patients with peritoneal surface metastases from mucinous adenocarcinoma of the appendix and colon. Ann Surg Oncol 2008; 15 (03) 738-744
- 57 Sluiter NR, de Cuba EM, Kwakman R. et al. Versican and vascular endothelial growth factor expression levels in peritoneal metastases from colorectal cancer are associated with survival after cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Clin Exp Metastasis 2016; 33 (04) 297-307
- 58 Fu Y, Nagy JA, Brown LF. et al. Proteolytic cleavage of versican and involvement of ADAMTS −1 in VEGF-A/VPF-induced pathological angiogenesis. J Histochem Cytochem 2011; 59 (05) 463-473
- 59 Zheng PS, Wen J, Ang LC. et al. Versican/PG-M G3 domain promotes tumor growth and angiogenesis. FASEB J 2004; 18 (06) 754-756
- 60 Boland CR, Goel A. Microsatellite instability in colorectal cancer. Gastroenterology 2010; 138 (06) 2073-2087.e3
- 61 Donehower LA, Creighton CJ, Schultz N. et al. MLH1-silenced and non-silenced subgroups of hypermutated colorectal carcinomas have distinct mutational landscapes. J Pathol 2013; 229 (01) 99-110
- 62 Yaeger R, Chatila WK, Lipsyc MD. et al. Clinical sequencing defines the genomic landscape of metastatic colorectal cancer. Cancer Cell 2018; 33 (01) 125-136.e3
- 63 Overman MJ, McDermott R, Leach JL. et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): an open-label, multicentre, phase 2 study. Lancet Oncol 2017; 18 (09) 1182-1191
- 64 Massalou D, Benizri E, Chevallier A. et al. Peritoneal carcinomatosis of colorectal cancer: novel clinical and molecular outcomes. Am J Surg 2017; 213 (02) 377-387
- 65 Flanagan DJ, Amirkhah R, Vincent DF. et al. Epithelial TGFβ engages growth-factor signalling to circumvent apoptosis and drive intestinal tumourigenesis with aggressive features. Nat Commun 2022; 13 (01) 7551
- 66 Mei ZB, Duan CY, Li CB, Cui L, Ogino S. Prognostic role of tumor PIK3CA mutation in colorectal cancer: a systematic review and meta-analysis. Ann Oncol 2016; 27 (10) 1836-1848
- 67 Wang Q, Shi YL, Zhou K. et al. PIK3CA mutations confer resistance to first-line chemotherapy in colorectal cancer. Cell Death Dis 2018; 9 (07) 739
- 68 Peerenboom R, Dhiman A, Witmer HDD. et al. PI3K pathway alterations in peritoneal metastases are associated with earlier recurrence in patients with colorectal cancer undergoing optimal cytoreductive surgery. Ann Surg Oncol 2023; (e-pub ahead of print). Doi:
- 69 Huo YR, Huang Y, Liauw W, Zhao J, Morris DL. Prognostic value of carcinoembryonic antigen (CEA), AFP, CA19-9 and CA125 for patients with colorectal cancer with peritoneal carcinomatosis treated by cytoreductive surgery and intraperitoneal chemotherapy. Anticancer Res 2016; 36 (03) 1041-1049
- 70 Verwaal VJ, Zoetmulder FAN. Follow-up of patients treated by cytoreduction and chemotherapy for peritoneal carcinomatosis of colorectal origin. Eur J Surg Oncol 2004; 30 (03) 280-285
- 71 Ihemelandu C. Inflammation-based prognostic scores: utility in prognostication and patient selection for cytoreduction and perioperative intraperitoneal chemotherapy in patients with peritoneal metastasis of colonic origin. Ann Surg Oncol 2017; 24 (04) 884-889
- 72 Narasimhan V, Tan S, Kong J. et al. Prognostic factors influencing survival in patients undergoing cytoreductive surgery with hyperthermic intraperitoneal chemotherapy for isolated colorectal peritoneal metastases: a systematic review and meta-analysis. Colorectal Dis 2020; 22 (11) 1482-1495
- 73 Jacquet P, Sugarbaker PH. Clinical research methodologies in diagnosis and staging of patients with peritoneal carcinomatosis. In: Sugarbaker PH, (edited book). Peritoneal Carcinomatosis: Principles of Management. Vol 82. New York, NY: Springer; 1996:359–374
- 74 Hallam S, Tyler R, Price M, Beggs A, Youssef H. Meta-analysis of prognostic factors for patients with colorectal peritoneal metastasis undergoing cytoreductive surgery and heated intraperitoneal chemotherapy. BJS Open 2019; 3 (05) 585-594
- 75 Hallam S, Stockton J, Bryer C. et al. The transition from primary colorectal cancer to isolated peritoneal malignancy is associated with an increased tumour mutational burden. Sci Rep 2020; 10 (01) 18900
- 76 Kozman MA, Fisher OM, Rebolledo BJ. et al. CEA to peritoneal carcinomatosis index (PCI) ratio is prognostic in patients with colorectal cancer peritoneal carcinomatosis undergoing cytoreduction surgery and intraperitoneal chemotherapy: a retrospective cohort study. J Surg Oncol 2018; 117 (04) 725-736
- 77 Kepenekian V, Aloy MT, Magné N. et al. Impact of hyperthermic intraperitoneal chemotherapy on Hsp27 protein expression in serum of patients with peritoneal carcinomatosis. Cell Stress Chaperones 2013; 18 (05) 623-630
- 78 Nimonkar AV, Genschel J, Kinoshita E. et al. BLM-DNA2-RPA-MRN and EXO1-BLM-RPA-MRN constitute two DNA end resection machineries for human DNA break repair. Genes Dev 2011; 25 (04) 350-362
- 79 Kwakman R, de Cuba EM, de Winter JP. et al. Tailoring heated intraperitoneal mitomycin C for peritoneal metastases originating from colorectal carcinoma: a translational approach to improve survival. Br J Cancer 2015; 112 (05) 851-856
- 80 McMullen JRW, Selleck M, Wall NR, Senthil M. Peritoneal carcinomatosis: limits of diagnosis and the case for liquid biopsy. Oncotarget 2017; 8 (26) 43481-43490